TIMOTHY J. YEATMAN, M.D.
PAGE 1
Updated 02/16/16
CURRICULUM VITAE
NAME:
Timothy J. Yeatman, M.D., F.A.C.S.
HOME ADDRESS:
17341 Morris Bridge Road
Thonotosassa, FL 33592
TELEPHONE:
(813) 782-3008
OFFICE ADDRESS:
H. Lee Moffitt Cancer Center and Research Institute
A National Cancer Institute Comprehensive Cancer Center
12902 Magnolia Drive – SRB-TCC
Tampa, FL 33612
TELEPHONE:
(813) 745-7292
PRESENT TITLE AND AFFILIATION:
Executive Vice President, Translational Research,
H. Lee Moffitt Cancer Center and Research Institute
Section Head, Hepatobiliary disease
University of South Florida
Tampa, Florida
Professor of Surgery
University of South Florida
Tampa, Florida
Senior Member, Biochemistry and Molecular Biology
University of South Florida
Tampa, Florida
President & Chief Scientific Officer,
M2Gen
DATE AND PLACE OF BIRTH:
6/10/1958, Cheverly, MD
EDUCATION:
Duke University
Durham, North Carolina
B.S. (Double Major: Zoology, Psychology)
Phi Beta Kappa, Summa Cum Laude, 1980
TIMOTHY J. YEATMAN, M.D.
PAGE 2
Updated 02/16/16
Emory University School of Medicine
Atlanta, Georgia
M.D., 1984
POST GRADUATE TRAINING:
University of Florida, College of Medicine
Gainesville, Florida
Internship, July 1984 - June 1985
University of Florida, College of Medicine
Gainesville, Florida
General Surgery Residency, July 1985 - June 1990
University of Texas M.D. Anderson Cancer Center
Houston, Texas
Fellow in Surgical Oncology, July 1990 - June 1992
AACR Post-Graduate Course
Workshop in Molecular Biology
Aspen, CO, July 1993
Stint in Laboratory of Arthur Pardee, Ph.D.
Dana Farber Cancer Institute
Boston, MA, August 1993
LICENSURES:
Licensed Physician and Surgeon
State of Florida, 1985
Certificate # 47461
Licensed Physician and Surgeon
State of Alabama, 1990
Certificate # 15488
Licensed Physician and Surgeon
State of Texas, 1990
Certificate # H9450
BOARD CERTIFICATIONS:
1985 National Board of Medical Examiners
Certificate # 295636
1991 Diplomate, American Board of Surgery
TIMOTHY J. YEATMAN, M.D.
PAGE 3
Updated 02/16/16
Certificate # 36060
ACADEMIC AND PROFESSIONAL APPOINTMENTS:
Animal Caretaker
National Institutes of Health
Building 10
Bethesda, MD
Summer, 1976
Teaching Assistant
Department of Zoology
Duke University
Durham, North Carolina
September 1978 - May 1979
Biologist
National Institutes of Health
Bethesda, Maryland
1977 - 1984 Consecutive Summer Appointments
Junior Faculty Associate
UT M.D. Anderson Cancer Center
Department of General Surgery
Houston, Texas
July 1990 - June 1992
Assistant Professor of Surgery
University of South Florida
College of Medicine
Department of Surgery, Department of Biochemistry & Molecular Biology
Tampa, Florida
July 1992 - 1996
Associate Professor of Surgery
University of South Florida
College of Medicine
Department of Surgery, Department of Biochemistry & Molecular Biology
Tampa, Florida
July 1996 – June 2000
Program Leader, GI Tumor Program
TIMOTHY J. YEATMAN, M.D.
PAGE 4
Updated 02/16/16
H. Lee Moffitt Cancer Center and Research Institute
at the University of South Florida
Tampa, Florida
May 1999 – August 2003
Professor of Surgery
University of South Florida
College of Medicine
Department of Surgery, Department of Biochemistry & Molecular Biology
Tampa, Florida
July 2000 - Present
Associate Chair of Education, Department of
Interdisciplinary Oncology
H. Lee Moffitt Comprehensive Cancer Center & Research Institute
At the University of South Florida
Tampa, Florida
August 2001-present
Interim Associate Center Director for
Clinical Investigations
H. Lee Moffitt Comprehensive Cancer Center & Research Institute
At the University of South Florida
Tampa, Florida
November 2002-August 2003
Associate Center Director for
Clinical Investigations
H. Lee Moffitt Comprehensive Cancer Center & Research Institute
At the University of South Florida
Tampa, Florida
August 2003-August 2005
Director of Total Cancer Care
H. Lee Moffitt Comprehensive Cancer Center & Research Institute
At the University of South Florida
Tampa, Florida
August 2005-present
Executive Vice President, Translational Research, MCC
President & Chief Scientific Officer, M2Gen
TIMOTHY J. YEATMAN, M.D.
PAGE 5
Updated 02/16/16
February 2007-present
Total Cancer Care is a broad initiative in personalized cancer care. Leveraging an
international network of 20 hospitals systems (Total Cancer Care Consortium), clinical
and molecular data are collected longitudinally from thousands of patients to identify
molecular signatures in cancer diagnosis, prognosis, and prediction response to therapy.
Patients are consented for lifetime follow-up with the promise of re-contact for the
purpose of a therapeutic clinical trial. The outcome is personalized cancer therapy that
will aid in linking patients and proper therapy. To date, more than 50,000 patients have
consented to participate, and 15,000 eligible snap frozen tumor tissue samples have been
collected. More than 12,000 tumor samples have been profiled with a whole genome
microarray analysis. Total Cancer Care holds promise to revolutionize the performance of
clinical trials through digital trial matching and gene-based trial matching and to improve
the quality and standard of care for cancer patients.
M2GEN (Moffitt 2nd Generation) is a wholly-owned, for-profit subsidiary of the nonfor profit MCC parent corporation funded by 45M from the State of Florida, Hillsborough
County, and the City of Tampa to become an “economic multiplier” for these entities. It
is a personalized medicine company that manages the Total Cancer Care Initiative,
specializing in tissue and data collection that will be used to help speed the delivery of
novel therapeutics translational clinical trials. The company is anticipated to incubate and
spin off new entities such as a contract research organization capable of personalized
medicine clinical trials.
COMPETITIVE GRANT SUPPORT:
Southern Medical Association
Co-Investigator
"Membrane changes associated with 5-fluorouracil resistance
of colon cancer cells"
July 1987 - June 1988
$ 2,500
American Cancer Society
Co-Investigator
"Tumor-specific interactions with hepatocyte receptors as a mechanism
for organ-specific metastasis of human colorectal cancer"
July 1987 - June 1988
$ 5,500
Immunomedics, Inc.
Principal Investigator
"A pilot study examining the feasibility of using immunolymphoscintigraphy to detect
and quantify breast cancer lymph node metastases: staging the axilla preoperatively using
TIMOTHY J. YEATMAN, M.D.
PAGE 6
Updated 02/16/16
the Tc-99m-labeled Fab' fragment of the anti-CEA antibody Immu-4"
January 1992 - January 1993
$75,000
University of South Florida
Principal Investigator
"A study of the endogenous phospholipases governing CEA release by human colorectal
cancer cells"
February 1993 - June 1994
$6,000
University of South Florida Creative Scholarship Award Grant
Principal Investigator
"Detection of genes associated with human colorectal liver metastasis by the differential
display method"
January 1994 - January 1995
$7,500
University of South Florida, Department of Surgery Seed Grant
Principal Investigator
"Detection of genes associated with human colorectal liver metastasis by the differential
display method"
1994
$5,000
American Cancer Society ACS 6120069LO
Principal Investigator
"Detection of genes associated with human colorectal liver metastasis by the differential
display method"
February 1994 - January 1995
$8,000
National Institutes of Health, National Cancer Institute
Principal Investigator
K-11 Physician Scientist's Award CA 65512-01
"Analysis of Colon Cancer Liver Metastasis mRNA's"
May 1995 - May 1998
$713,787
American Cancer Society, National
Co-Investigator
RPG-97-031-01DHP
TIMOTHY J. YEATMAN, M.D.
PAGE 7
Updated 02/16/16
“Electrochemotherapy for the Treatment of Liver Malignancies"
January 1997 - December 1998
$187,000
American Cancer Society, National
Principal Investigator
RPG-MGO-97551
“Src Activation in Colon Cancer"
January 1999 - December 2001
$299,000
National Institutes of Health, National Cancer Institute
Co-Investigator
P20-CA91353-03 (PI, Pledger)
05/2001 – 04/2003
“Puerto Rico Partnership”
Partnership between the H. Lee Moffitt Cancer Center and the Puerto Rico Cancer Center
to share expertise and enhance development.
National Institutes of Health, National Cancer Institute
Senior Leader and Scientific Director of Data Management Core and Protocol Specific
Support.
P30-CA76292-06 (PI, Dalton)
02/19/98–01/31/07
“H. Lee Moffitt Cancer Center and Research Institute Support Grant”
$1,832,856
Department of Defense
Co-Investigator
DAMD17-02-2-0051 (PI – Pledger)
09/01/03-03/31/06
National Functional Genomics Center
Prediction of Response of Gastroesophageal Junction Tumors to Neoadjuvant
Chemoradiotherapy with Expression Profiling
$50,000
National Institutes of Health, National Cancer Institute
Principal Investigator
Director’s Challenge: Toward a Molecular Classification of Tumors (CA-98-027)
“Decoding Fingerprints Portending Colon Cancer Metastasis”
09/07/00 – 01/31/06 (no cost extension)
$5,469,696
TIMOTHY J. YEATMAN, M.D.
PAGE 8
Updated 02/16/16
National Institutes of Health, National Cancer Institute
Principal Investigator
K24 – Midcareer Investigator Award In Patient Oriented Research (PA-98-053)
“SRC as a Novel Target for Human Colon Cancer Therapy”
09/30/00 – 08/31/05
$615,545
National Institutes of Health (TPA-99-064)
Co-Investigator
K12-CA87989-02 (PI – Zuckerman)
"Clinical Scholars in Oncology"
7/1/01-6/30/06
$2,694,737
James and Esther King Agency (State of Florida)
Co-Investigator
“Functional Role of Mcm 7-Rb Interaction in Res Signaling and Yumorigenesis”
06-NIR-01
07/01/2006-06/30/2009
National Institutes of Health: Moffitt Aging and Cancer
CO- Principal Investigator
5P20CA103676-05
“Age-Related Genetic Immunological Profiles in Breast Cancer”
09/01/2007-08/31/08
National Cancer Institute
Principal Investigator
R01-CA098522
“Screening for Breast Cancer Using Molecular Signatures”
08/18/03 – 07/31/08
$3,139,402
National Cancer Institute
Collaborator
RO1 CA120316-01A1
“Mapping Gene Networks in Colon Cancer”
12/01/06 – 11/30/10
$21,527—total costs
National Cancer Institute
TIMOTHY J. YEATMAN, M.D.
PAGE 9
Updated 02/16/16
Principal Investigator
1 R01 CA 112215-01A2
“Chip-Based Diagnosis of Problematic Liver Tumors”
8/10/06 - 7/31/11
$2,155,00 – total costs
James and Esther King Agency/ Bankhead Coley (State of Florida)
Principal Investigator
08BR-02
“Molecular Signatures for Colon Cancer”
7/1/08- 6/30/11
$1,250,000 – total costs
OTHER GRANT SUPPORT:
Dupont Pharmaceuticals
“Alpha V Beta 3 Gene Expression in Cancer”
2000 - 2001
$5,000
Roche Laboratories
“Src Inhibitors for Cancer”
June 2000 – June 2002
$100,000
Pfizer
Principal Investigator
Molecular Analysis of Colon Cancer
Sponsored Therapeutic Trial
August 2005 - present
$450,000
Roche
Principal Investigator
Molecular Analysis of Colon Cancer
Sponsored Therapeutic Trial
June 2005 - present
$250,000
MEMBERSHIPS:
1992-Present, Society of Surgical Oncology
TIMOTHY J. YEATMAN, M.D.
PAGE 10
Updated 02/16/16
Active Member
1993-2002, Association for Academic Surgery
Program Committee Member
1993-Present, American Association for Cancer Research
Active Member
1994-1999, American Association for the Advancement of Science
Active Member
1996 American College of Surgeons
Fellow
1996-Present, The Society of University Surgeons
Active Member
1997, American Hepato-Pancreato-Biliary Association
Active Member
1998-2000, The Society for Surgery of the Alimentary Tract
Active Member
2001-Present, Edward R Woodward Society
Active Member
2004, Florida Cancer Clinical Trial Cooperative, Inc.
Board-of-Directors
2005- Florida Society of Clinical Oncology
Ad-hoc-committee member
2005-2006, American Cancer Society
Director-at-Large
2005, Society of Surgical
Member of CME and Program Committee
2006, Association of Community Cancer Centers
Active Member
2006, Society of Surgical Oncology
Vice Chair of Scientific Program Committee
2007, Society of Surgical Oncology
Chair of the Scientific Program Committee
EDITORIAL BOARDS
Journal of Clinical Oncology
Annals of Surgical Oncology
Cancer Control
Molecular Oncology
Clinical Cancer Research (CCR)
NATIONAL COMMITTEES
The Society of Surgical Oncology Scientific Program Committee – 2005-present
TIMOTHY J. YEATMAN, M.D.
PAGE 11
Updated 02/16/16
American Cancer Society Colorectal Task Force – 1999-present
The Society of Surgical Oncology Examination Committee- 1996-present
The Society of Surgical Oncology Web Site Committee - 1996-present
NCCN Gastrointestinal Tumor Group - 1999-2002
AD HOC REVIEWER
Nature Genetics
Cancer Cell
Cancer Research
Clinical Cancer Research
Journal of Surgical Research
Gastroenterology
Annals of Surgical Oncology
Cancer: Interdisciplinary International Journal of the American Cancer Society
Clinical and Experimental Metastasis Journal
Cancer Control Journal: Journal of the H. Lee Moffitt Cancer Center
British Journal of Surgery
British Journal of Cancer
VA Merit Review
International Journal of Cancer
Nucleic Acids Research
Oncogene
SOCIETY OFFICES
Association for Academic Surgery Program Committee 1998-2000
Committee on Issues 1999-2001
Nominating Committee 2001-2002
Society of Surgical Oncology –
Vice Chair, Scientific Program Committee 2006-2007
Scientific Program Committee 2005-2006
Education Committee 1998-2000
Website Development Committee 1999-2002
HONORS AND AWARDS:
Washington Heart Association
Outstanding Student Scholarship Award, 1975
American Cancer Society
TIMOTHY J. YEATMAN, M.D.
PAGE 12
Updated 02/16/16
Competitive Scientific Scholarship Award, 1976
Phi Beta Kappa, Summa Cum Laude
Duke University
Durham, North Carolina, 1980
American Cancer Society
Clinical Research Fellowship Award
$ 7,000 1987 – 1988
Outstanding Resident Research Award
University of Florida, College of Medicine
Gainesville, Florida, 1989
American Cancer Society
Research Training Grant Recipient - Two-year recipient
$ 30,000 July 1990 – 1992
Center Director's Award for Outstanding Research
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, 1995
James Ewing Foundation Trainee Award
Society of Surgical Oncology, 1997
Center Director's Award for Outstanding Research
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, 1997
Center Director's Award for Outstanding Research
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, 1998
James IV Association of Surgeons
Travelling Fellowship
Europe, 2001
SSO Bakers Travel Award
March, 2002
Excellence in Research Award
American College of Surgeons
TIMOTHY J. YEATMAN, M.D.
PAGE 13
Updated 02/16/16
Jimmy Sung, Surgical Resident
University of South Florida-Mentored resident
2005
TEACHING:
Clinical Instructor - Surgical Residents
College of Medicine, Department of Surgery
University of South Florida
Tampa, Florida
Clinical Instructor - Medical students
College of Medicine/Gene Therapy
University of South Florida
Tampa, Florida
Instructor - Medical Students
College of Medicine, Department of Biochemistry
& Molecular Biology
University of South Florida
Tampa, Florida
Clinical Instructor - Core Lectures
Physician’s Assistant Program
University of Florida, College of Medicine
Gainesville, Florida, 1988
Clinical Instructor - Core Lectures
Department of Physical Therapy
University of Florida, College of Medicine
Gainesville, Florida, 1988
Laboratory Instructor
Introductory Zoology
Duke University
Durham, North Carolina
September 1978 - May 1979
STUDENTS MENTORED
Jonathan Hernandez, M.D. – Surgical Resident
TIMOTHY J. YEATMAN, M.D.
PAGE 14
Updated 02/16/16
Alexander Li, B.S. – Harvard University College of Medicine
James Huang, M.D. – Surgical Resident
Emilia Dauway, M.D. – Surgical Oncology Fellow
Nicole Nicosia – University of South Florida
Rosalyn Irby, Ph.D. - Post Doctoral Fellow
Weiguang Mao, M.D. - Post Doctoral Fellow
Anneris Paredes, M.D.- Pathology Fellow
Leigh Judah - University of South Florida
Priya Naman - Yale University
David R. Lane - Swarthmore College
Jimmy Kang - Harvard University
Jimmy Sung – Surgical Resident, University of South Florida, 2005
Quan Ly – Surgical Resident, University of South Florida, present
Michael Alvarado - Post Doctoral Fellow, University of South Florida, present
Eric Jensen - Post Doctoral Fellow, University of South Florida, present
Cindy Timme - Doctoral Student, MCC, present
PROFESSIONAL AFFILIATIONS
American Association for Cancer Research
American College of Surgeons
American Association for Advancement of Science
Association for Academic Surgery
The Society of Surgical Oncology
The Society for Surgery of the Alimentary Tract
American Society of Clinical Oncology
The Society of University Surgeons
Tampa Bay Surgical Society
UNIVERSITY RELATED SERVICES
USF Search Advisory Committee for the Vice President for Health Sciences
and Dean, College of Medicine - 2004
Chair, Department of Surgery Research Committee - 1999
Scientific Review Committee –1995
Infectious Disease Committee -1994
College Of Medicine Faculty Affairs Committee-1994
Laboratory Animal Medicine Ethics Committee -1993
TIMOTHY J. YEATMAN, M.D.
Updated 02/16/16
PAGE 15
TIMOTHY J. YEATMAN, M.D.
PAGE 16
Updated 02/16/16
PUBLICATIONS
1.
Attallah AM, Yeatman TJ, Noguchi PD, Petricciani JC. Is DNA synthesis a requisite for
the differentiation of B lymphocytes into immunoglobulin-secreting plasma cells? Int
Arch Allergy Appl Immun. 1979;60(2):132-139.
2.
Attallah AM, Fleisher T, Neefe JR, Kazakis A, Noguchi PD, Yeatman TJ. Differential
effect of human interferon on normal and neoplastic T and B cell lymphocytes. Ann NY
Acad Sci. 1980;350:245-253.
3.
Attallah AM, Yeatman TJ, Noguchi PD, Johnson JB. Antibody-dependent cell-mediated
cytotoxicity detected by automated flow cytometry with ultramicro techniques. Science.
1980 Jul;209(4454):404-406.
4.
Attallah AM, Lewis FA, Urritia-Shaw A, Folks T, Yeatman TJ. Natural killer cells (NK)
and antibody-dependent cell-mediated cytotoxicity (ADCC) components of Schistosoma
mansoni infection. Int Arch Allergy Appl Immun.1980;63(3):351-354.
5.
Attallah AM, Urritia-Shaw A, Yeatman TJ, Folks T. Effect of the new immunosuppressive agent cyclosporin-A on natural killer cell and ADCC activity. Int Arch
Allergy Appl Immunol. 1981;65(4):465-469.
6.
Attallah AM, Yeatman TJ. ADCC analysis with the Coulter counter: a highly sensitive,
ultramicro assay suitable for clinical and experimental application. J Immunol Methods.
1981;43(2):121-129.
7.
Attallah AM, Zoon K, Folks T, Yeatman TJ. Multiple biological activities of
homogenous human alpha interferon. Infect and Immunol. 1981 Dec;34(3):1068-1070.
8.
Attallah AM, Yeatman TJ. Is there a role for biotechnology and genetic engineering in
Egypt’s future. In: Galal S, ed. The five conferences of Egypt in the year 2000. Cairo,
Egypt: Al-Ahram Press; 1982.
9.
Attallah AM, Yeatman TJ, Johnson RP, Petricciani JC. Biological response modifiers
and their promise in clinical medicine. Pharmacol and Ther. 1982;19(3):435-454.
10.
Attallah AM, Yeatman TJ. Determination of surface antigens using the Coulter counter:
a simple, highly-sensitive method. Diagn Immunol. 1983;1(1):39-42.
11.
Yeatman TJ. Emphysematous cholecystitis: an insidious variant of acute cholecystitis.
Am J Emer Med. 1986 Mar;4(2):163-166.
TIMOTHY J. YEATMAN, M.D.
PAGE 17
Updated 02/16/16
12.
Yeatman TJ, Smith VC. Thymoma. Surg Rounds 1986;9(2):121-124.
13.
Yeatman TJ, Seagle MB, Cassisi NJ. A rare manifestation of metastatic adenocarcinoma.
The Laryngoscope. 1986 Jun;96(6):692-4.
14.
Yeatman TJ, Sharp JV, Kimura AK. Can susceptibility to carcinoid tumors be inherited?
Cancer. 1989 Jan;63(2):390-393.
15.
Yeatman TJ, Bland KI, Copeland EM, III, Kimura AK. Tumor cell-surface galactose
correlates with the degree of colorectal liver metastasis. J Surg Res. 1989
Jun;46(6):567-571.
16.
Yeatman TJ, Bland KI, Copeland EM, III, Hollenbeck JI, Vogel SB, Souba WW, Kimura
AK. Relationship between colorectal liver metastases and CEA levels in gallbladder bile.
Ann Surg. 1989;210(4):505-512.
17.
Yeatman TJ, Bland KI. Sphincter-saving procedures for distal carcinoma of the rectum.
Ann Surg. 1989 Jan;209(1):1-18.
18.
Yeatman TJ, Bland KI. Colorectal liver metastasis. Postgrad Gen Surg.
1989;1(8):45-51.
19.
Yeatman TJ, Bland KI. The basis for surgical decisions in the management of in-situ
breast cancer. Comprehen Ther. 1990 May;16(5):12-17.
20.
Yeatman TJ, Bland KI, Copeland EM, III, Kimura AK. Rapid Analysis of
Carcinoembryonic Antigen Levels in Gallbladder Bile: Identification of Patients at High
Risk for Colorectal Liver Metastasis. Ann Surg. 1991 Feb;213(2):113-117.
21.
Yeatman TJ, Vogel SV, Bland KI. Hepatic resection: when? why? how? In: Levine BA,
Maier RV, Bland KI, eds. Perspectives Gen Surg. St. Louis, Missouri: Quality Medical
Publishing, Inc; 1991:2(1):57-76.
22.
Yeatman TJ, Risley GL, Brunson MT. Depletion of dietary arginine inhibits growth of
metastatic tumor. Arch Surg. 1991Nov;126(11):1376-1382.
23.
Yeatman TJ, Weber RS, Balch CM. The contemporary management of skin cancers. In:
Levine BA, Copeland EM, III, Warshaw AL, Howard RJ, Sugerman H, eds. Current
Practice of Surgery. New York: Churchill-Livingstone; 1992.
24.
Tressler RJ, Updyke TV, Yeatman TJ, Nicolson GL. Extracellular annexin II is
associated with divalent cation-dependent tumor cell-endothelial cell adhesion of
TIMOTHY J. YEATMAN, M.D.
PAGE 18
Updated 02/16/16
metastatic RAW 117 large-cell lymphoma cells. J Cell Biol. 1993;53:265-276.
25.
Yeatman TJ, Updyke TV, Dedman JR, Nicolson GL. Expression of annexins on the
surfaces of non-metastatic and metastatic human and rodent tumor cells. Clin Exp
Metastasis. 1993 Jan;11(1):37-44.
26.
Yeatman TJ, Nicolson GL. Molecular Basis of Tumor Progression: Mechanism of
Organ-specific Tumor Metastasis. Semin Surg Onc. 1993 May-Jun;9(3):256-263.
27.
Nicolson GL, Yeatman TJ, Tressler RJ, Updyke TV, Hamada J, Cavanaugh PG. Tumor
cell-endothelial cell interactions during blood-borne metastasis: role of specific adhesion,
motility, and growth molecules. In: Hemler ME, Mihich E, eds. Pezcoller Foundation
Sympsia Series. New York: Plenum Press; 1993:221-243.
28.
Kim EE, Podoloff DA, Moulopoulos LA, Hortobagyi GH, Yeatman TJ, Singletary SE.
Magnetic Resonance Imaging, Positron Emission Tomography, and
Radioimmunoscintigraphy of Breast Cancer. Cancer Bulltn. 1993;45(6):500-505.
29.
Yeatman TJ, Duan C, Mao W, Karl RC, Djeu J. Augmentation of Carcinoembryonic
Antigen Release from Intact, Viable, Tumor Cells by a Factor in Human Serum. Ann Surg
Oncol. 1995 Jul;2(4):336-342.
30.
Yeatman TJ, Mao W, Karl RC, Djeu J. Phospholipase C - gamma1 is present on the
surface of human colorectal cancer cells. Biochem Biophys Res Commun. 1994
Jun:201(2);1043-49.
31.
Tressler RJ, Yeatman TJ, Nicolson GL. Extracellular annexin VI expression is associated
with divalent cation-dependent endothelial cell adhesion of metastatic RAW 117 large-cell
lymphoma cells. Exp Cell Res. 1994:215;395-400.
32.
Yeatman TJ. The natural history of locally advanced primary breast carcinoma and
metastatic disease. In: Bland KI (ed). Surgical Oncology Clinics of North America.
1995 Oct;4 (4):569-89.
33.
Yeatman TJ, Karl RC. Molecular basis for chemoprevention of colorectal carcinogenesis.
J Fla Med Assoc. 1995 May;82(5):360-3.
34.
Yeatman TJ, Cantor AB, Smith TJ, et al. Tumor biology of infiltrating lobular carcinoma.
Implications for management. Ann Surg. 1995 Oct:222,(4);559-561.
35.
Yeatman TJ, Mao W. Identification of a differentially-expressed message associated
with colon cancer liver metastasis using an improved method of differential display.
TIMOTHY J. YEATMAN, M.D.
PAGE 19
Updated 02/16/16
Nucleic Acids Res. 1995 Oct;23(19):4007-4008.
36.
Reintgen D, Lyman G, Yeatman T. Non-operative observation of mammographic
abnormalites: medical legal implications. Breast Journal. 1995;1(4):262-267.
37.
Yeatman TJ, Cher ML, Mao W, Wloch M, Tedesco, Thomas. Identification of genetic
alterations associated with the process of human experimental colon cancer liver
metastasis in the nude mouse. Clin Exp Metastasis. 1996 May;14(3):246-252.
38.
Marcet J, Yeatman, TJ. Avoiding Colostomy with Conservative Multimodality
Management of Distal Rectal Cancer. Cancer Control. 1996 Jan;3(1):26-33.
39.
Yeatman TJ , Lyman GH, Smith SK, Reintgen DS, Cantor AB, Cox CE. Bilaterality and
recurrence rates for lobular breast cancer: considerations for treatment. Ann Surg Onc.
1997 Apr-May; 4(3):198-202.
40.
Yeatman TJ, Mao W, Karl RC. Biliary glycoprotein is overexpressed in human colon
cancer cells with high metastatic potential. J Gastro Surg. 1997 May;1(3):292-298.
41.
Mao W, Yeatman TJ, Karl RC, Jove R. c-Src activation by epidermal growth factor
through receptor family kinases may potentiate humnan colon cancer liver metastasis.
Surgical Forum. 1996;67:507-510.
42.
Karl RC, Choi JC, Yeatman TJ, Clark RC. Role of computed tomographic arterial
portography (CTAP) and intraoperative ultrasound (IOUS) in the evaluation of patients for
resectability of hepatic lesions. J Gastro Surg. 1997 Mar;1(2):152-158.
43.
Chouhdry U, Boyce HW, Johnson M, Marcet J, Yeatman TJ. Role of endoscopic
ultrasonography (EUS) in preoperative staging of rectal cancer. Gastro Intest Endosc.
1996;43(4):417.
44.
Huffman JL, Yeatman TJ and Smith JB. Leptomeningeal Carcinomatosis: A Sequela of
Cholangiocarcinoma. Am. Surg. 1997 Apr; 63(4):310-313.
45.
Albertini JJ, Lyman GH, Cox CE, Yeatman TJ, et al. Lymphatic mapping and sentinel
node biopsy in patients with breast cancer. JAMA. 1996 Dec.;276:1818-1822.
46.
Reintgen D, Emmanuella J, Lyman GH, Yeatman TJ, et al. The Role of Selective
Lymphadenectomy in Breast Cancer. Cancer Control. 1997;4(3):211-219.
47.
Mao W, Irby R, Copolla D, Fu L, Wloch M, Turner J, Yu H, Garcia R, Jove R, Yeatman
T. Activation of c-Src by Receptor Tyrosine Kinases in Human Colon Cancer Cells with
TIMOTHY J. YEATMAN, M.D.
PAGE 20
Updated 02/16/16
High Metastatic Potential. Oncogene. 1997 Dec; 15(25):3083-3090.
48.
Irby R, Mao W, Coppola D, Jove R, Gamero A, Cuthbertson D, Fujita D, Yeatman TJ.
Overexpression of Normal c-Src in Poorly-Metastatic Human Colon Cancer Cells
Enhances Primary Tumor Growth but not Metastatic Potential. Cell Growth &
Differentiation. 1997 Dec;8(12):1287-1295.
49.
Coppola D, Lu L, Fruehauf JP, Kyshtoobayeva A, Karl RC, Nocosia SV, Yeatman TJ.
Analysis of p53, p21, WAF1 and TGFPancreas: TGFAm J Clin Pathol. 1998
Jul; 110(1):16-23.
50.
Cox CE, Pendas S, Cox JM, Joeph E, Shons AR, Yeatman T, Ku NN, Lyman GH,
Berman C, Haddad F, Reintgen DS. Guidelines for Sentinel Node Biopsy and Lymphatic
Mapping of Patients with Breast Cancer. Ann. Surg. 1998 May;227(5):645-51.
51.
Iravani S, Mao W, Fu L, Jove R, Yeatman T, Karl R, Coppola D. Elevated c-Src Protein
Expression Is an Early Event in Colonic Neoplasia. Laboratory Investigation. 1998;
(79)3;365-371.
52.
Paredes-Zaglul A, Kang JJ, Essig Y, Mao W, Irby I, Wloch M, Yeatman TJ. Analysis of
Colorectal Cancer by Comparative Genomic Hybridization: Evidence for Induction of the
Metastatic Phenotype by Loss of Tumor Suppressor Genes. Clinical Cancer Research.
1998 Apr; 4(4):879-886.
53.
Cox CE, Haddad F, Bass S, Cox JM, Ku NN, Berman C, Shons AR, Yeatman TJ, Pendas
S, Reintgen DS. Lymphatic Mapping in the Treatment of Breast Cancer. Oncology.
1998; 12:1283-1298.
54.
Cox C, Bass S, Ku N, Berman C, Shons A, Yeatman T, Reintgen D. Sentinal
Lymphadenectomy: a safe answer to less axillary surgery. Recent Results Cancer
Research. 1998;152:170-9.
55.
56.
Irby R, Mao W, Coppola D, Kang J, Loubeau JM, Jove R, Fujita DJ, Karl R, Yeatman
TJ. A Naturally Occurring Mutation In Human c-SRC Is Activating, Transforming, and
Augmenting Metastatic Potential. Surgical Forum. American College of Surgeons;
1998; Chapter 10 - Surgical Oncology.
Irby R, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita D, Jove R,
Yeatman TJ. Activating SRC mutation in a subset of advanced human colon cancers.
Nature Genetics. 1999 February;21(2):187-190.
TIMOTHY J. YEATMAN, M.D.
PAGE 21
Updated 02/16/16
57.
Yeatman TJ, Moazam F, Talbert JL. Evaluation and treatment of an unusual neck mass in
a child. Surgical Rounds. February 1999; vol.22 (2); 77-79.
58.
Yeatman TJ, Cox CE. The Significance of Breast Cancer Lymph node Micrometastases.
Surgical Oncology Clinics of North America – Radioguided Surgery. 1999 July;8(3);
481-496.
59.
Hakam A, Yeatman TJ, Lu L, Mora L, Marcet J, Nicosia SV, Karl RC, Coppola D.
Expression of Insulin-like Growth Factor-1 Receptor in Human Colorectal Cancer.
Human Pathology. 1999 October;30(10); 1128-1133.
60.
Cox CE, Yeatman TJ, Salus CJ, Bass SS. Significance of Sentinel Node Micrometastasis.
Cancer Control. Nov./Dec. 1999; vol. 6 (6); 601-605.
61.
Haddad FF, Yeatman TJ, Shivers SC, Reintgen DS. The human genome project: a dream
becoming a reality. Surgery. 1999 June;125(6): 575-580.
62.
Yeatman TJ. Colon Cancer. Encyclopedia of Life Sciences. 2000
63.
Yeatman TJ. Gallbladder Bile CEA and Occult Hepatic Metastases from Colorectal
Cancer. Diseases of the Colon & Rectum. September 2000.
64.
Yeatman TJ. Nutritional Support for the Surgical Oncology Patient. Cancer Control
Journal. 2000 Nov-Dec;7(6):563-5.
65.
Huang J, Qi R, Quackenbush J, Dauway E, Lazaridis E, Yeatman T. The Effects of
Ischemia on Gene Expression. J Surg Res. 2001 Aug;99(2):343-6.
66.
Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer.
Oncogene. 2000 Nov 20;19(49):5636-42.
67.
Benson AB, Choti MA, Cohen AM, Doroshow JH, Fuchs C, Kiel K, Martin EW, McGinn
C, Petrelli NJ, Skibber JM, Venook A, Yeatman TJ. NCCN Practice Guidelines for
Colorectal Cancer. Oncology (Huntingt). 2000 Nov;14(11A):203-12.
68.
Teng S, Sun J, Irby R, Sebti S, Yeatman T. V-Src Transformation is Mediated Through
Farnesylated Proteins. J Surg Res. 2001;Aug;99(2):343-6.
69.
Kim CJ, Yeatman T, Coppola D, Trotti A, Williams B, Barthel JS, Dinwoodie W, Karl
RC, Marcet J. Local Excision of T2 and T3 Rectal Cancers After Downstaging
Chemoradiation. Annals of Surgery, 2001 September;234(3):352-359.
TIMOTHY J. YEATMAN, M.D.
PAGE 22
Updated 02/16/16
70.
Bowman T, Broome M, Sinibaldi D, Wharton W, Pledger WJ, Sedivy J, Irby R, Yeatman
T, Courtneidge S, Jove R. Stat3-mediated Myc expression is required for Src
transformation and PDGF-induced mitogenesis. PNAS. 2001 June;98(13):7319-7324.
71.
Hedge P, Qi R, Gaspard R, Abernathy K, Dharap S, Earle-Hughes J, Gay C, Nwokekeh
NU, Chen T, Saeed AI, Sharov V, Lee NH, Yeatman TJ, Quackenbush J. Identification of
tumor markers in models of human colorectal cancer using a 19,200 element cDNA
microarray. Cancer Research. 2001 Nov;61(21):7792-7797.
72.
Kim CJ, Reintgen DS, Yeatman TJ. The Promise of Microarray Technology in
Melanoma Care. Cancer Control. 2002 January/February; 9(1):49-53.
73.
Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola
D, Yeatman T. Osteopontin Identified as Lead Marker of Colon Cancer Progression
Using Pooled Sample Expression Profiling. JNCI, 2002 Apr 3;94(7):513-21.
74.
Irby RB, Yeatman TJ. Increased Src Activity Disrupts Cadherin/Catenin-Mediated
Homotypic Adhesion in Human Colon Cancer and Transformed Rodent Cells. Cancer
Research. 2002 May 1;62(9):2669-74.
75.
Malek, RL, Irby RB, Guo QM, Lee K, Wong S, He M, Tsai J, Frank B, Liu ET,
Quackenbush J, Jove R, Yeatman TJ, Lee NH. Identification of Src Transformation
Fingerprint in Human Colon Cancer. Oncogene Oct. 2002, 21(47):7256-7265.
76.
Yang IV, Chen E, Hasseman JP, Liang W, Frank BC, Wang s, Sharov V, Saeed AI, White
J, Li J, Lee NH, Yeatman TJ and Quackenbush J. Within the fold: assessing differential
expression measures and reproducibility in microarray assays. Genome Biology Oct.
2002, 3(11).
77.
Reed J, Ouban A, Schickor FK, Muraca P, Yeatman T, Coppola D. Immunohistochemical
staining for c-kit (CD117) is a rare event in human colorectal carcinoma. Clin Colorectal
Cancer. 2(2):119-22, August 2002.
78.
Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola
D, Yeatman, TJ. Osteopontin identified as colon cancer tumor progression marker.
Proceedings of the French Academy of Sciences in the special issue “From Functional
Genomics to Systems Biology.” Comptes Rendus - Biologies 2003 Oct.-Nov.;326(1011):1041-1043.
79.
Yeatman, TJ. The Future of Cancer Management:Translating the Genome,
Transcriptome, and Proteome. Ann. Surg. Oncol., 10(1):7-14, Jan-Feb. 2003.
TIMOTHY J. YEATMAN, M.D.
PAGE 23
Updated 02/16/16
80.
Yeatman, TJ. The Future of Clinical Cancer Management: One Tumor, One Chip. The
American Surgeon, 69(1):41-4, Jan. 2003.
81.
Yeatman TJ, Chambers AF. Osteopontin and Colon Cancer Progression. Clin Exp
Metastasis. 20(1):85-90, 2003.
Chen T, Yang I, Irby R, Shain KH, Wang HG, Quackenbush J, Coppola D, Cheng JQ,
Yeatman TJ. Regulation of caspase expression and apoptosis by adenomatous polyposis
coli. Cancer Research, 63, 4368-4374, Aug. 1, 2003.
82.
83.
Ouban A, Muraca P, Yeatman T, Coppola D. Expression and distribution of insulin-like
growth factor-1 receptor in human carcinomas. Hum Pathol. 2003 Aug;34(8):803-8.
84.
Yeatman, TJ. Beyond p53. (Editorial). Annals of Surgical Oncology. 10(8):831, Oct.
2003.
85.
Durkin AJ, Bloomston PM, Rosemurgy AS, Giarelli N, Cojita D, Yeatman TJ, Zervos
EE. Defining the role of the epidermal growth factor receptor in pancreatic cancer grown
in vitro. Am J Surg. 2003 Nov;186(5):431-6.
86.
Bloom G, Yang I, Boulware D, Kwong KY, Coppola D, Eschrich S, Quackenbush J,
Yeatman TJ. Multi-Platform, Multi-Site, Microarray-Based Human Tumor
Classification. American Journal of Pathology, 164(1):9-16, Jan. 2004.
87.
Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ.
Correlation of osteopontin protein expression and pathological stage across a wide variety
of tumor histologies. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90.
88.
Nasir A, Kaiser HE, Boulware D, Hakam A, Zhao H, Yeatman T, Barthel J, Coppola D.
Cyclooxygenase-2 expression in right- and left-sided colon cancer: a rationale for
optimization of cyclooxygenase-2 inhibitor therapy. Clin Colorectal Cancer. 2004
Feb;3(4):243-7.
89.
Wang J, Gamsby J, Highfill SL, Mora LB, Bloom GC, Yeatman TJ, Pan TP, Ramne AL,
Chodosh LA, Cress WD, Chen J, Kerr WG. Deregulated expression of LRBA facilitates
cancer cell growth. Oncogene. 2004 May 20;23(23):4089-97.
90.
Bloomston M, Durkin A, Yang I, Rojiani M, Rosemurgy AS, Enkemann S, Yeatman TJ,
Zervos EE. Identification of molecular markers specific for pancreatic neuroendocrine
tumors by genetic profiling of core biopsies. Ann Surg Oncol. 2004 Apr;11(4):413-9.
91.
Nasir A, Boulware D, Kaiser HE, Bodey B, Siegel S, Crawley S, Yeatman T, Marcet JE,
Coppola D. Flat and polypoid adenocarcinomas of the colorectum: A comparative
TIMOTHY J. YEATMAN, M.D.
PAGE 24
Updated 02/16/16
histomorphologic analysis of 47 cases. Hum Pathol. 2004 May;35(5):604-11.
92.
Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004 Jun;4(6):470-80.
93.
Eschrich S, Yeatman T. DNA microarrays and data analysis: An overview. Surgery.
2004 Sept;136(3):500-3.
94.
Solmi R, De Sanctis P, Zucchini C, Ugolini G, Rosati G, Del Governatore M, Coppola D,
Yeatman TJ, Lenzi L, Caira A, Zanotti S, Taffurelli M, Carinci P, Valvassori L and
Strippoli P. Search for epithelial-specific mRNAs in peripheral blood of patients with
colon cancer by RT-PCR. International Journal of Oncology. 2004 Oct;25(4):10491056.
95.
Chen T, Turner J, McCarthy S, Scaltriti M, Bettuzzi S, Yeatman TJ. Clusterin Mediated
Apoptosis is Regulated by APC and is P21 Dependent but P53 Independent. Can Res.
2004 Oct: 64:7412–7419.
96.
Durkin AJ, Bloomston M, Yeatman TJ, Gilbert-Barness E, Cojita D, Rosemurgy AS,
Zervos E. Differential Expression of the Tie-2 Receptor and its Ligands in Human
Pancreatic Tumors. American College of Surgeons. 2004 Nov:199(5):724-731.
97.
Irby RB, McCarthy SD, Yeatman TJ. Osteopontin regulates multiple functions
contributing to human colon cancer development and progression. Clinical &
Experimental Metastasis. 21(6): 515-523, December 2004.
98.
Sung J, Turner J, McCarthy S, Enkemann S, Li CG, Yan P, Huang T, Yeatman TJ.
Oncogene Regulation of Tumor Suppressor Genes in Tumorigenesis. Carcinogenesis.
2005 Feb;26(2):487-494.(Senior Author)
99.
Dobbin KK, Beer DG, Meyerson M, Yeatman TJ, Gerald WL, Jacobson JW, Conley B,
Buetow KH, Heiskanen M, Simon RM, Minna JD, Girard L, Misek DE, Taylor J, Hanash
S, Naoki K, Hayes DN, Ladd-Acosta C, Enkemann SA, Viale A and Giordano TJ. Interlaboratory Comparability Study of Cancer Gene Expression Analysis Using
Oligonucleotide Microarrays. Clinical Cancer Research. 11:565-572. January 15, 2005.
(Hypothesis Development)
100.
Helm J, Enkemann S, Coppola D, Barthel JS, Kelley ST, Yeatman TJ. DeDifferentiation Precedes Invasion in the Progression from Barrett’s Metaplasia to
Esophageal Adenocarcinoma. Clinical Cancer Research 2005;11(7) April
1,2005.(Senior Author)
101.
Irby RB, Marek RL, Bloom G, Tsai J, Letwin N, Frank BC, Verratti K, Yeatman TJ and
TIMOTHY J. YEATMAN, M.D.
PAGE 25
Updated 02/16/16
Lee NH. Iterative Microarray and RNA Interference-Based Interrogation of the SrcInduced Invasive Phenotype. Cancer Res 2005;65:(5). March 1, 2005. (Hypothesis
Development)
102.
Centeno BA, Enkemann SA, Coppola D, Huntsman S, Bloom G, Yeatman TJ.
Classification of human tumors using gene expression profiles obtained after microarray
analysis of fine-needle aspiration biopsy samples. Cancer. 2005 Apr 25;105(2):1019.(Senior Author)
103.
Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhøffer
M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ. Molecular Staging for
Survival Prediction of Colorectal Cancer Patients. Journal Clinical Oncology. 2005
May 20;23(15):3526-35.(Senior Author)
104.
Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ,
Chambers AF. Osteopontin induces multiple changes in gene expression that reflect the
six "hallmarks of cancer" in a model of breast cancer progression. Mol Carcinog. 2005
Aug;43(4):225-236. (Hypothesis Development)
105.
Kwong KY, Bloom GC, Yang I, Boulware D, Coppola D, Haseman J, Chen E, McGrath
A, Makusky AJ, Taylor J, Steiner S, Zhou J, Yeatman TJ, Quackenbush J. Synchronous
global assessment of gene and protein expression in colorectal cancer progression.
Genomics. 2005 Jun 9; Genomics. 2005 Aug;86(2):142-58. (Hypothesis Development)
106.
Engstrom PF, Benson AB 3rd, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG,
Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saif MW, Saltz
L, Skibber JM, Venook AP, Yeatman TJ. Colon cancer clinical practice guidelines in
oncology .J Natl Compr Canc Netw. 2005 Jul;3(4):468-91.(Senior Author)
107.
Engstrom PF, Benson AB 3rd, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG,
Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saif MW, Saltz
L, Skibber JM, Venook AP, Yeatman TJ. Rectal cancer clinical practice guidelines in
oncology. J Natl Compr Canc Netw. 2005 Jul;3(4):492-508. (Senior Author)
108.
Engstrom PF, Benson AB 3rd, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG,
Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saif MW, Saltz
L, Skibber JM, Venook AP, Yeatman TJ. Anal canal cancer clinical practice guidelines
in oncology. J Natl Compr Canc Netw. 2005 Jul;3(4):510-5.(Senior Author)
109.
Kelley ST, Coppola D, Yeatman T, Marcet J. Tumor Response to Neoadjuvant
Chemoradiation Therapy for Rectal Adenocarcinoma Is Mediated by p53-Dependent and
Caspase 8-Dependent Apoptotic Pathways. Clin Colorectal Cancer. 2005 Jul;5(2):114-
TIMOTHY J. YEATMAN, M.D.
PAGE 26
Updated 02/16/16
8. (Hypothesis Development)
110.
Sung J, Lee YA, Yeatman T. The promise of gene signatures in cancer diagnosis and
prognosis. Encyclopedia of Genetics, Genomics, Proteomics, and Bioinformatics.
2005 July 15(Senior Author)
111.
Torres-Roca JF, Eschrich S, Zhao H, Bloom G, Sung J, McCarthy S, Cantor AB, Scuto
A, Li C, Zhang S, Jove R, Yeatman T. Prediction of radiation sensitivity using a gene
expression classifier. Cancer Res. 2005 Aug 15;65(16):7169-76.(Senior Author)
112.
Nasir A, Stridsberg M, Strosberg J, Su PH, Livingston S, Malik HA, Kelley ST, Centeno
BA, Coppola D, Malafa ME, Yeatman TJ, Kvols LK. Somatostatin Receptor profiling
in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms:
immunohistochemical approach with potential clinical utility. Cancer Control. 2006
Jan;13(1):52-60. (Hypothesis Development)
113.
Alvarado MD, Jensen EH, Yeatman TJ. The Potential Role of Gene Expression in the
Management of Primary and Metastatic Colorectal Cancer. Cancer Control. 2006
Jan;13(1):27-31.(Senior Author)
114.
Bloomston M, Zhou JX, Rosemurgy AS, Frankel W, Muro-Cacho CA, Yeatman TJ.
Fibrinogen Gamma Overexpression in Pancreatic Cancer Identified By Large Scale
Proteomic Analysis of Serum Samples. Cancer Res. 2006; 66: (5). March 1, 2006.(Senior
Author)
115.
Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, Yeatman TJ,
Carey L, Duhaine L, Kvols LK. Improved outcome with cytoreduction versus
embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine
tumors. Ann Surg Oncol. 2006 Apr;13(4):572-81. (Hypothesis Development)
116.
Yeatman TJ. Carcinoembryonic antigen, biomarker discovery, and trial design.
(Editorial). Annals of Surgical Oncology. 2006 May;13(5):600-1.(First Author)
117.
Jensen EH, McLoughlin JM, Yeatman TJ. Microarrays in gastrointestinal cancer: is
personalized prediction of response to chemotherapy at hand? Current Opinion in
Oncology. 2006 July;18(4):374-80.(Senior Author)
118.
Durkin AJ, Osborne DA, Yeatman TJ, Rosemurgy AS, Armstrong C, Zervos EE. EGF
receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma.
Journal Surgical Research. 2006 Sep;135(1):195-201. (Hypothesis Development)
119.
Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, Centeno B, Weber F,
TIMOTHY J. YEATMAN, M.D.
PAGE 27
Updated 02/16/16
Leu YW, Shapiro CL, Eng C, Yeatman TJ, Huang TH. Mapping geographic zones of
cancer risk with epigenetic biomarkers in normal breast tissue. Clinical Cancer
Research. 2006;12(22) Nov 15, 2006. (Hypothesis Development)
120.
Goldin, S, Kelley S, Windham C, Yeatman TJ. Colorectal Cancer book chapter, Pocket
Surgical Oncology. November 2006(Senior Author)
121.
Ly QP., Yeatman TJ. Clinical Relevance of Targeted Interference with Src-Mediated
Signal Transduction Events. Cancer Research. 2007, 172:169-188.(Senior Author)
122.
Hodul PJ, Yeatman TJ. TNM Staging is Obsolete. (Editorial). Journal of Surgical
Oncology. 2007 Jan 1;95(1):8-9.(Senior Author)
123.
Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ, Freudenberg J, Chen X,
Haigis K, Jegga AG, Kong S, Sakthivel B, Xu H, Reichling T, Azhar M, Boivin GP,
Roberts RB, Bissahoyo A, Gonzales F, Bloom GL, Eschrich S, Carter, SL, Aronow JE,
Kleimeyer J, Kleimeyer M, Ramaswamy V, Settle SH, Boone B, Levy S, Graff JM,
Doetschman T, Groden J, Dove WF Threadgill DW, Yeatman TJ, Coffey RJ, Aronow
BJ. Transcriptional recapitulation and subversion of embryonic colon development by
mousde colon tumor models and human colon cancer. Genome Biology. 2007, 8:R131.
(Hypothesis Development)
124.
Jensen EH, Kvols L, McLoughlin JM, Lewis JM, Alvarado MD, Yeatman T, Malafa M,
Shibata D. Biomarkers predict outcomes following cytoreductive surgery for hepatic
metastases from functional carcinoid tumors. Ann Surg Oncol. 2007 Feb; 14 (2):780-5.
(Hypothesis Development)
125.
BloomGC, Eschrich S, Zhou JX, Yeatman, TJ. Elucidation of a Protein Signature
Discriminating Six Common Types of Adenocarcinoma. International Journal of
Cancer. 2007 Feb 15; 120(4): 769-75.(Senior Author)
126.
Jensen EH, Lewis JM, McLoughlin JM, Alvarado MD, Daud A, Messina J, Enkemann S,
Yeatman TJ, Sondak VK, Riker AI. Down Regulation of Pro Apoptiotic Genes is an
Early Event in the Progression of Malignant Melanoma. Ann Surg Oncol. 2007,
14(4):1416-23. (Hypothesis Development)
127.
Yeatman TJ, Architecture of the Future of Personalized Medicine: Radical Re-design of
Drug Development. Asian Hospital & Healthcare Management. 2007 Jul; 13:32-33.
(First Author)
128.
McCarthy S, Caporali A, Enkemann S, Scaltriti M, Eschrich S, Davalli P, Corti A, Lee A,
Sung J, Yeatman TJ, Bettuzzi S. Identification of MCM7 as a proliferation biomarker
TIMOTHY J. YEATMAN, M.D.
PAGE 28
Updated 02/16/16
that responds to green tea catechins: chemoprevention in the TRAMP model of prostate
cancer. Mol Oncology. 2007 Sep;1 (2)196-204 (Hypothesis Development)
129.
Salgam O, Garrett CR, Boulware D, Sayegh Z, Shibata D, Malafa M, Yeatman T, Cheng
JQ, Sebti S, Coppola D. Activation of the serine/threonine protein kinase AKT during the
progression of colorectal neoplasia. Clin Colorectal Cancer. 2007 Sep; 6(9): 652-6
(Hypothesis Development)
130.
Scuto A, Zhang H, Zhao H, Rivera M, Yeatman TJ, Jove R, Torres-Roca JF. RbAp48
regulates cytoskeletal organization and morphology by increasing K-Ras activity and
signaling through mitogen-activated protein kinase. Cancer Res. 2007 Nov 1;67(21):103
17-24. (Hypothesis Development)
131.
Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, Bao S, Cheng AW, Lin F, Jiang S,
Yeatman TJ, Wang XF. Extracellular matrix protein {beta}ig-h3/TGFBI promotes
metastasis of colon cancer by enhancing cell extravasation. Genes Dev. 2008 Feb
1;22(3):308-21. (Hypothesis Development)
132.
Gilkes DM, Pan Y, Coppola D, Yeatman T, Reuther GW, Chen J. Regulation of
MDMX expression by mitogenic signaling. Mol Cell Biol. 2008 Mar;28(6)1999-2010.
(Hypothesis Development)
133.
Cheng AS, Culhane AC, Chan MW, Venkataramu CR, Ehrich M, Nasir A, Rodriguez
BA, Liu J, Yan PS, Quackenbush J, Nephew KP, Yeatman TJ, Huang TH. Epithelial
progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome.
Cancer Research. 2008 Mar 15;68(6):1786-96. (Hypothesis Development)
134.
Elahi A, Zhang L, Yeatman TJ, Gery S, Sebti S, Shibata D. HPP1-mediated tumor
suppression requires activation of STAT1 pathways. Int J. Cancer. 2008 Apr 1;
122(7):1567-72. (Hypothesis Development)
135.
Kline CL, Jackson R, Engelman R, Pledger WJ, Yeatman TJ, Irby RB. Src kinase
induces tumor formation in the c-SRC C57BL/6 mouse. Int J. Cancer. 2008 Jun
15;122(12):2665-79 (Hypothesis Development)
136.
Yamaguchi H, Woods NT, Dorsey JF, Takahashi Y, Gjertsen NR, Yeatman T, Wu J,
Wang HG. SRC directly phosphorylates Bif-1 and prevents its interaction with Bax and
the initiation of anoikis. J Biol Chem. 2008 Jul 4;283(27):19112-8. Epub 2008 May 12.
(Hypothesis Development)
137.
Li CG, Gruidl M, Eschrich S, McCarthy S, Wang HG, Alexandrow MG, Yeatman TJ.
Insig2 is associated with colon tumorigenesis and inhibits Bax-mediated apoptosis. Int J
TIMOTHY J. YEATMAN, M.D.
PAGE 29
Updated 02/16/16
Cancer. 2008 Jul 15;123(2):273-82. (Senior Author)
138.
Chen DT , Schell MJ , Chen JJ , Fulp WJ , Eschrich S, Yeatman TJ. A Predictive Risk
Probability Approach for Microarray Data with Survival as an Endpoint. J of
Biopharmaceutical Statistics. 2008;18 (5):841-52 (Senior Author)
139.
Director's Challenge Consortium for the Molecular Classification of Lung
Adenocarcinoma, Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald
WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D,
Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R,
Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M,
Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK,
Lively T, Jacobson JW, Beer DG.Gene expression-based survival prediction in lung
adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008 Aug; 14(8):822-7.
Epub 2008 Jul 20. (Hypothesis Development)
140.
Yeatman TJ, Mule J, Dalton WS, Sullivan D. On the eve of personalized medicine in
oncology. Cancer Res. 2008 Sep 15: 68(18):7250-2. (First Author)
141.
Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M,
Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA,
Dalton WS. Proteomic contributions to personalized cancer care. Mol Cell Proteomics.
2008 Oct; 7(10):1780-94 Epub 2008 July 29. Review. (Hypothesis Development)
142.
Nair RM, Siegel EM, Chen DT, Fulp WJ, Yeatman TJ, Malafa MP, Marcet J, Shibata D.
Long-Term Results of Transanal Excision After Neoadjuvant Chemoradiation for T2 and
T3 Adenocarcinomas of the Rectum. J Gastrointest Surg. 2008 Oct;12(10): 1797-805;
discussion 1805-6 Epub 2008 Aug 15. (Hypothesis Development)
143.
Helm JF, Centeno BA, Coppola D, Druta M, Park JY, Chen DT, Hodul PJ, Kvols LK,
Yeatman TJ, Carey LC, Karl RC, Malafa MP. Outcomes following resection of
pancreatic adenocarcinoma: 20-year experience at a single institution. Cancer Control.
2008 Oct;15(4): 288-94. (Hypothesis Development)
144.
Coppola D, Khalil F, Eschrich SA, Boulware D, Yeatman T, Wang HG. Downregulation of Bax-interacting factor-1 in colorectal adenocarcinoma. Cancer. 2008 Nov
15; 113(10): 2665-70. (Hypothesis Development)
145.
Jorissen RN, Lipton L, Gibbs P, Chapman M, Desai J, Jones IT, Yeatman TJ, East P,
Tomlinson IP, Verspaget HW, Asltonen LA, Kruhoffer M, Orntoft TF, Anderson CL,
Sieber OM. DNA copy-number alterations underlie gene expression differences between
microsatellite stable and unstable colorectal cancers. Clin Cancer Res. 2008 Dec
TIMOTHY J. YEATMAN, M.D.
PAGE 30
Updated 02/16/16
15;14(24): 8061-9. (Hypothesis Development)
146.
Chen DT, Nasir A, Venkataramu C, Fulp W, Gruidl M, Yeatman T. Evaluation of
malignancy-risk gene signature in breast cancer patients. Breast Cancer Res Treat. 2009
Mar 22.(Senior Author)
147.
Xu BJ, Li J, Beauchamp RD, Shyr Y, Li M, Washington MK, Yeatman TJ, Whitehead
RH, Coffey RJ, Caprioli RM. Identification of early intestinal neoplasia protein
biomarkers using laser capture microdissection and MALDI MS. Mol Cell Proteomics.
2009 May;8(5):936-45. (Hypothesis Development)
148.
Yeatman TJ. Predictive biomarkers: identification and verification. J Clin Oncol. 2009
June 10;27(17):2743-4. (First Author)
149.
Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J. SirT1
is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem. 2009
Jul 3;284(27):18210-7. Epub 2009 May 11. (Hypothesis Development)
150.
Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, Rocha-Lima
C, Kelley S, Calvin DP, Yeatman TJ, Begg AC, Torres-Roca JF. A gene expression
model of intrinsic tumor radiosensitivity: prediction of response and prognosis after
chemoradiation. Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):489-96. (Hypothesis
Development)
151.
Krishnan M, Singh AB, Smith JJ, Sharma A, Chen X, Eschrich S, Yeatman TJ,
Beauchamp RD, Dhawan P. HDAC inhibitors regulate claudin-1 expression in colon
cancer cells through modulation of mRNA stability. Oncogene. 2009 Nov 2. (Hypothesis
Development)
152.
Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt
C, Edwards CM, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ,
Yeatman TJ, Shyr Y, Beauchamp RD. Experimentally Derived Metastasis Gene
Expression Profile Predicts Recurrence and Death in Patients With Colon Cancer.
Gastroenterology. 2009 Nov 13. (Hypothesis Development)
153.
Nasir A, Shackelford RE, Anwar F, Yeatman TJ. Genetic risk of breast cancer. Minerva
Endocrinol. 2009 Dec;34(4):295-10.(Senior Author)
154.
Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, Kerr D, Aaltonen LA,
Arango D, Kruhøffer M, Orntoft TF, Andersen CL, Gruidl M, Kamath VP, Eschrich S,
Yeatman TJ, Sieber OM. Metastasis-Associated Gene Expression Changes Predict Poor
Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clin Cancer Res.
TIMOTHY J. YEATMAN, M.D.
PAGE 31
Updated 02/16/16
2009 Dec 15;15(24):7642-7651. (Hypothesis Development)
155.
Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R, Wang T, Agrawal D,
McCarthy SM, Gruidl M, Bloom G, Anderson T, White J, Quackenbush J, Yeatman T.
Proliferative genes dominate malignancy-risk gene signature in histologically-normal
breast tissue. Breast Cancer Res Treat. 2010 Jan;119(2):335-46. Epub 2009 Mar 6.
(Senior Author)
BOOK CHAPTERS
1. Yeatman TJ, Bland KI, Copeland EM, III. Malignant lesions of the colon, rectum, and
anus. In: Moody FG et al, eds. Surgical Treatment of Digestive Diseases. Chicago:
Yearbook Med Pub, Inc; 1990:799-816.
2. Yeatman TJ, Bland KI. Staging of Breast Cancer Staging. In: Bland KI and Copeland
EM, III, eds. The Breast: Comprehensive Management of Benign and Malignant
Diseases. New York: W.B. Saunders; 1991:313-330.
3. Yeatman TJ, Bland KI. Operative considerations II: sphincter saving procedures for
operable rectal cancer. In: Cohen AM, Winawer SJ, eds. Cancer of the Colon, Rectum
and Anus. New York: McGraw Hill Inc; 1994:571-577.
4. Yeatman TJ, Copeland EM, III. CEA directed second-look surgery. In Cameron JE:
Curr Surg Ther, 5 ed. 1994;195-199.
5. Karl RC, Yeatman TJ. Molecular screening and prevention of colon cancer. In: Reintgen
DS, Clark R (eds). Cancer Screening. Mosby Yearbook, Inc. St. Louis, 1996; 221-38.
6. Yeatman TJ, Bland KI. Staging of Breast Cancer Staging. In: Bland KI and Copeland
EM, III, eds. The Breast: Comprehensive Management of Benign and Malignant
Diseases. New York: W.B. Saunders. 2nd edition, 1997.
7. Yeatman TJ, Bland KI. Staging of Breast Cancer Staging. In: Bland KI and Copeland
EM, III, eds. The Breast: Comprehensive Management of Benign and Malignant
Diseases, vols 1 & 2. Philadelphia, Pa, Saunders, 2004.
8. Yeatman TJ, Sung J, Lee A. Diagnosis and treatment of malignancies using gene
expression. The Oncogenomics Handbook. 2004.
9. Sung JC, Lee, AY, Yeatman TJ, Fundamentals of Cancer Genomics and Proteomics,
Chapter 91, Surgery: Basic Science and Clinical Evidence, Second Edition, SpringerVerlag New York 2008. (Senior Author)
TIMOTHY J. YEATMAN, M.D.
PAGE 32
Updated 02/16/16
OTHER
EXTERNAL ADVISORY BOARDS
Vanderbilt GI Spore
HTG Scientific Advisory Board, 2010
NIH SITE VISITS
Cornell Clinical Research Center,1996.
PO-1 MSKCC/Rockerfeller University Evaluation, 2000
PO-1 Burnham Institute
INVITED LECTURESHIPS:
Keynote speaker –British Journal Surgery lecture
SARS (The Society of Academic and Research Surgery) Inaugural meeting
London, 2002
UAB-Dept of Surgery Grand Rounds-West Pavilion-Birmingham, AL
Visiting Professor, “The Genetics of Colon Cancer Progression” - September 27, 2001
The University of Missouri, School of Medicine, Department of Surgery
Visiting Professor, "The Genetics of Colon Cancer" - April 7, 2001
NCI REVIEWS:
University of Michigan, 2008
University of Utah, Huntsman Cancer Institute, 2009